INVO FERTILITY TO IMPLEMENT 1:5 REVERSE STOCK SPLIT STARTING MARCH 27, 2026, BEFORE MARKET OPENING
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy IVF?
Source: moomoo
Announcement of Stock Split: Invofertility has announced a 1:5 reverse stock split.
Effective Date: The reverse stock split will take effect on March 27, 2026, during pre-market trading.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IVF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IVF
About IVF
INVO Fertility Inc., formerly NAYA Biosciences, Inc., is a healthcare services company focused on the fertility marketplace and expanding access to assisted reproductive technology (ART) care for patients in need. Its segments include Fertility Clinic Services, INVOcell Device, and Therapeutics. It focuses on operating fertility clinics, including INVO Centers dedicated primarily to offering the intravaginal culture (IVC) procedure enabled by its INVOcell medical device (INVOcell) and United States-based, in vitro fertilization (IVF) clinics. It has two operational INVO Centers in the United States and one IVF clinic. It is also engaged in the sale and distribution of its INVOcell technology solution to third party-owned and operated fertility clinics. The INVOcell is a proprietary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a natural, intimate, and affordable experience.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
INVO Fertility Announces 1-for-5 Reverse Stock Split
- Reverse Split Implementation: INVO Fertility announced a 1-for-5 reverse stock split effective March 27, 2026, which will reduce the outstanding shares from approximately 8,077,095 to about 1,615,419, thereby increasing the per-share price and enhancing market perception.
- Trading Symbol Unchanged: Post-split, the company's common stock will continue to trade under the same symbol 'IVF' on the Nasdaq Capital Market, which will help maintain investor recognition and market stability.
- Shareholder Rights Adjustment: All shareholders will have their holdings adjusted according to the reverse split ratio, with every 5 shares exchanged for 1 share, ensuring no loss of shareholder equity while providing cash compensation for fractional shares.
- Market Strategy Focus: INVO Fertility is dedicated to expanding assisted reproductive technology (ART) services, planning to enhance market share by establishing and operating more fertility clinics, and the reverse split will provide greater flexibility for future capital operations.
See More
INVO FERTILITY TO IMPLEMENT 1:5 REVERSE STOCK SPLIT STARTING MARCH 27, 2026, BEFORE MARKET OPENING
Announcement of Stock Split: Invofertility has announced a 1:5 reverse stock split.
Effective Date: The reverse stock split will take effect on March 27, 2026, during pre-market trading.
See More
INVO Fertility Integrates Time-Lapse Incubation Technology
- Technology Adoption: INVO Fertility has integrated time-lapse incubation technology at its Wisconsin clinic, aiming to enhance laboratory care quality and patient service, reflecting the company's commitment to modern reproductive treatments.
- Significant Patient Benefits: Continuous embryo monitoring through time-lapse imaging provides detailed developmental insights, aiding embryologists in making informed clinical decisions, thereby improving embryo selection success rates and increasing patient engagement.
- Consistency in Care: Patients can receive video records of their embryo's development without added complexity, which not only enhances their understanding of the process but also boosts their confidence in the treatment.
- Strategic Investment Focus: The adoption of this technology underscores INVO Fertility's commitment to investing in advanced technologies, aiming to expand access to fertility care through ongoing innovation and strengthen its competitive position in the reproductive services market.
See More
INVO Fertility Completes Acquisition of Family Beginnings Clinic
- Acquisition Completed: INVO Fertility has successfully closed the acquisition of Family Beginnings for $760,000, marking a significant milestone in the company's strategy to expand its network of fertility care centers, which is expected to enhance patient service quality and accessibility.
- Financial Performance: Family Beginnings generated approximately $1 million in revenue and $200,000 in net income for the nine months ended September 30, 2025, accounting for about 18% of INVO's clinic revenue during the same period, indicating its solid market position.
- Leadership Continuity: The existing medical leadership and care teams at Family Beginnings will remain in place post-acquisition, ensuring continuity of patient care while benefiting from INVO's clinical resources and technological investments to enhance service levels.
- Strategic Expansion: This acquisition aligns closely with INVO's strategic goals to increase market share through organic growth and targeted acquisitions, with CEO Steve Shum emphasizing the importance of this transaction in enhancing the company's geographic footprint and service capabilities.
See More
INVO FERTILITY COMPLETES PURCHASE OF INDIANA FERTILITY CLINIC "FAMILY BEGINNINGS"
Acquisition Announcement: Invofertility has completed the acquisition of an Indiana-based fertility clinic named "Family Beginnings."
Focus on Fertility Services: The acquisition aims to enhance fertility services and support for families seeking assistance in starting or expanding their families.
See More
INVO Fertility Secures New Patent Protection
- Patent Protection Expansion: INVO Fertility announced the final issuance of U.S. Patent No. 12,544,204 B2 on February 10, 2026, covering its modified INVOcell® device, ensuring intellectual property protection until 2040, thereby enhancing the company's competitive edge in the fertility technology market.
- Innovative Medical Device: INVOcell is the world's first FDA-cleared intravaginal culture system that allows fertilization and early embryo development to occur within a woman's body, offering a more natural alternative to traditional in vitro fertilization, which is expected to attract more patients seeking fertility treatments.
- Design Simplification: The newly patented device features a simplified design with a single main chamber, eliminating the microchamber based on clinical feedback, aimed at enhancing user experience and improving treatment outcomes, thus driving further growth in the fertility market.
- Strategic Market Support: CEO Steve Shum stated that the patent issuance marks an important milestone in strengthening INVO Fertility's intellectual property foundation, supporting the company's mission to deliver high-quality fertility care through ongoing innovation, which is expected to facilitate future business growth.
See More
INVO Fertility Announces 1-for-5 Reverse Stock Split
- Reverse Split Implementation: INVO Fertility announced a 1-for-5 reverse stock split effective March 27, 2026, which will reduce the outstanding shares from approximately 8,077,095 to about 1,615,419, thereby increasing the per-share price and enhancing market perception.
- Trading Symbol Unchanged: Post-split, the company's common stock will continue to trade under the same symbol 'IVF' on the Nasdaq Capital Market, which will help maintain investor recognition and market stability.
- Shareholder Rights Adjustment: All shareholders will have their holdings adjusted according to the reverse split ratio, with every 5 shares exchanged for 1 share, ensuring no loss of shareholder equity while providing cash compensation for fractional shares.
- Market Strategy Focus: INVO Fertility is dedicated to expanding assisted reproductive technology (ART) services, planning to enhance market share by establishing and operating more fertility clinics, and the reverse split will provide greater flexibility for future capital operations.
See More
INVO FERTILITY TO IMPLEMENT 1:5 REVERSE STOCK SPLIT STARTING MARCH 27, 2026, BEFORE MARKET OPENING
Announcement of Stock Split: Invofertility has announced a 1:5 reverse stock split.
Effective Date: The reverse stock split will take effect on March 27, 2026, during pre-market trading.
See More
INVO Fertility Integrates Time-Lapse Incubation Technology
- Technology Adoption: INVO Fertility has integrated time-lapse incubation technology at its Wisconsin clinic, aiming to enhance laboratory care quality and patient service, reflecting the company's commitment to modern reproductive treatments.
- Significant Patient Benefits: Continuous embryo monitoring through time-lapse imaging provides detailed developmental insights, aiding embryologists in making informed clinical decisions, thereby improving embryo selection success rates and increasing patient engagement.
- Consistency in Care: Patients can receive video records of their embryo's development without added complexity, which not only enhances their understanding of the process but also boosts their confidence in the treatment.
- Strategic Investment Focus: The adoption of this technology underscores INVO Fertility's commitment to investing in advanced technologies, aiming to expand access to fertility care through ongoing innovation and strengthen its competitive position in the reproductive services market.
See More
INVO Fertility Completes Acquisition of Family Beginnings Clinic
- Acquisition Completed: INVO Fertility has successfully closed the acquisition of Family Beginnings for $760,000, marking a significant milestone in the company's strategy to expand its network of fertility care centers, which is expected to enhance patient service quality and accessibility.
- Financial Performance: Family Beginnings generated approximately $1 million in revenue and $200,000 in net income for the nine months ended September 30, 2025, accounting for about 18% of INVO's clinic revenue during the same period, indicating its solid market position.
- Leadership Continuity: The existing medical leadership and care teams at Family Beginnings will remain in place post-acquisition, ensuring continuity of patient care while benefiting from INVO's clinical resources and technological investments to enhance service levels.
- Strategic Expansion: This acquisition aligns closely with INVO's strategic goals to increase market share through organic growth and targeted acquisitions, with CEO Steve Shum emphasizing the importance of this transaction in enhancing the company's geographic footprint and service capabilities.
See More
INVO FERTILITY COMPLETES PURCHASE OF INDIANA FERTILITY CLINIC "FAMILY BEGINNINGS"
Acquisition Announcement: Invofertility has completed the acquisition of an Indiana-based fertility clinic named "Family Beginnings."
Focus on Fertility Services: The acquisition aims to enhance fertility services and support for families seeking assistance in starting or expanding their families.
See More
INVO Fertility Secures New Patent Protection
- Patent Protection Expansion: INVO Fertility announced the final issuance of U.S. Patent No. 12,544,204 B2 on February 10, 2026, covering its modified INVOcell® device, ensuring intellectual property protection until 2040, thereby enhancing the company's competitive edge in the fertility technology market.
- Innovative Medical Device: INVOcell is the world's first FDA-cleared intravaginal culture system that allows fertilization and early embryo development to occur within a woman's body, offering a more natural alternative to traditional in vitro fertilization, which is expected to attract more patients seeking fertility treatments.
- Design Simplification: The newly patented device features a simplified design with a single main chamber, eliminating the microchamber based on clinical feedback, aimed at enhancing user experience and improving treatment outcomes, thus driving further growth in the fertility market.
- Strategic Market Support: CEO Steve Shum stated that the patent issuance marks an important milestone in strengthening INVO Fertility's intellectual property foundation, supporting the company's mission to deliver high-quality fertility care through ongoing innovation, which is expected to facilitate future business growth.
See More
